SLS SELLAS Life Sciences Group Inc

On January 14, 2021, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) in which it disclosed that it had estimated cash and cash equivalents of approximately $35.3 million as of December 31, 2020.  The estimated cash and cash equivalents as of December 31, 2020 are preliminary and may change, are based on information available to management as of the date of the Press Release, and are subject to completion by management of the financial statements as of and for the year ended December 31, 2020. There can be no assurance that our cash and cash equivalents as of December 31, 2020 will not differ from these estimates, including as a result of quarter-end closing and any such changes could be material. Complete annual results will be included in our Annual Report on Form 10-K for the year ended December 31, 2020. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein.

The press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS for various cancer indications, including AML, ovarian cancer and MPM, the potential for regulatory approval and commercialization of GPS, statements related to the clinical development of NPS for breast cancer, including DCIS. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on SELLAS’ clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 13, 2020 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.